On account of γ-H2AX production conferring poor prognosis in different types of cancer including TNBC and NSCLC, and our in vivo efficacy of SUV39H2 inhibition in two model systems, SUV39H2 may possess therapeutic potential in a wide range of human cancers. This evidence concerns the gene H2AX and cancer.